Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) has undergone a significant leadership transition, with co-founder and president Eric So assuming the role of interim chief executive officer effective September 2, 2025. This change follows the departure of Doug Drysdale from the CEO position, marking a pivotal moment for the late-stage neuropsychiatry company as it advances its clinical pipeline of innovative mental health treatments.
The board of directors has established a committee to conduct a comprehensive search for a new permanent CEO who will lead the company through its commercialization phase. During this transition period, So will focus on maintaining continuity while advancing Cybin's promising clinical programs, particularly CYB003 and CYB004, which represent groundbreaking approaches to treating major mental health conditions.
This leadership change holds substantial importance for the mental healthcare landscape and investors alike. Cybin is positioned as a breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing next-generation treatment options that address the large unmet needs of people suffering from mental health conditions. The company's work represents a significant shift in how mental health disorders might be treated in the future, moving beyond traditional pharmaceutical approaches.
Cybin's clinical pipeline includes CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to address serious conditions where current treatments fall short. The company is also developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder, along with a research pipeline of investigational compounds focused on 5-HT receptors.
The leadership transition comes at a critical juncture for the company as it moves closer to potential commercialization of its novel therapies. Investors and stakeholders can access the latest news and updates relating to CYBN through the company's newsroom at https://ibn.fm/CYBN. The appointment of a co-founder as interim CEO suggests a strategic approach to maintaining corporate vision and operational stability during this period of change, ensuring that the company's groundbreaking work in mental health treatment continues without interruption.
